SEC Form 4 · accession 0001209191-15-045335

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

May 19, 2015

Accepted (ET)

May 21, 2015 · 4:08 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	May 19, 2015	G	41,000	$0.00	D	345,284	D
Common Stock	May 20, 2015	M	1,300	$17.16	A	346,584	D
Common Stock	May 20, 2015	M	10,400	$35.64	A	356,984	D
Common Stock^F3,F4	May 20, 2015	S	1,000	$125.07	D	355,984	D
Common Stock^F4,F5	May 20, 2015	S	9,000	$126.75	D	346,984	D
Common Stock^F4,F6	May 20, 2015	S	1,700	$127.62	D	345,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock^F7	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F8	$17.16	May 20, 2015	M	1,300	D	—	Jul 19, 2015	Common Stock	1,300	10,900	D
Stock Option (right to buy)^F8	$35.64	May 20, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	375,200	D

F1Represents gifts made to three charitable foundations.
F2Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F3Open market sales reported on this line occurred at a weighted average price of $125.07 (range $124.59 to $125.45).
F4Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F5Open market sales reported on this line occurred at a weighted average price of $126.75 (range $126.27 to $127.15).
F6Open market sales reported on this line occurred at a weighted average price of $127.62 (range $127.28 to $127.90).
F7Common stock held in grantor retained annuity trusts.
F8Fully vested.